Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
Submitted by
admin
on November 2, 2022 - 10:51pm
Source:
Motley Fool
News Tags:
Denali Therapeutics
clinical trials
Alzheimer's disease
TAK-594
Headline:
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
snippet:
Denali Therapeutics specializes in treating neurodegenerative disorders.
The company released preliminary phase 1/2 data on an Alzheimer's therapy.
Denali isn't profitable, but it does have $1.16 billion in cash.
Do Not Allow Advertisers to Use My Personal information
